Author Correction: Targeting cardiac fibrosis with engineered T cells
Haig Aghajanian(Therapeutics Clinical Research), Jonathan A. Epstein(University of Pennsylvania), Ellen Puré(University of the Sciences), Wei Han(Harbin Medical University), Steven Μ. Albelda(University of Pennsylvania), Aidan S. Hancock(California Institute for Regenerative Medicine), Carl H. June(University of Pennsylvania), James Monslow(University of Pennsylvania), Albert Lo(University of Pennsylvania), Rajan Jain(Penn Center for AIDS Research), Joel G. Rurik(Karolinska Institutet), Kenneth Bedi(University of Pennsylvania), Tao Wang(Kunming University of Science and Technology), Michael S. Leibowitz(Children's Hospital of Philadelphia), Dagmar Wirth(Helmholtz Centre for Infection Research), Cheryl L. Smith(California Institute for Regenerative Medicine), Kendra S. McDaid(University of Pennsylvania), Michael P. Morley(University of Pennsylvania), Nikhita Bolar(California Institute for Regenerative Medicine), Tōru Kimura(Josai University), Charles‐Antoine Assenmacher(University of Pennsylvania), John Scholler(University of Pennsylvania), Ricardo A. Linares Saldana(California Institute for Regenerative Medicine), Li Li(California Institute for Regenerative Medicine), Kenneth B. Margulies(Temple University)
Cited by 7
Related Papers
Adhesion molecules and inflammatory injury
|The FASEB Journal|1994|1k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure
|Nature Communications|2020|924
CAR T Cell Therapy for Solid Tumors
|Annual Review of Medicine|2016|866
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799